Free Trial!
Today’s Best Stocks To Trade! Click Here
Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. Regulation SHO mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.
Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI | Quote | Chart | News | PowerRating) a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. This segment's products under development include AllerNase, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis; and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida. With 43.18 million shares outstanding and 1.35 million shares declared short as of May 2008, the failure to deliver in shares of ABPI has not been resolved and a buy-in is imminent. According to quarterly data provided by the SEC, there were still 121,208 shares of ABPI that were failing-to-deliver as of September 28, 2007.
Great Southern Bancorp Inc. (NASDAQ: GSBC | Quote | Chart | News | PowerRating) operates as the bank holding company for Great Southern Bank, which offers financial services to customers primarily in southwest and central Missouri. The company accepts regular savings accounts, checking accounts, various money market accounts, fixed-interest rate certificates with varying maturities, certificates of deposit, brokered certificates, and individual retirement accounts. It also offers one- to four-family adjustable-rate residential mortgage loans, multi family real estate loans, and commercial real estate loans; construction loans; secured consumer loans, including automobile loans, home equity loans, and loans secured by savings deposits; improvement loans, guaranteed student loans; and unsecured consumer loans. In addition, the company provides general property, casualty, and life insurance agency services; personal, commercial, and group travel services; and investment and related services. As of December 31, 2007, it operated 38 branches located in southwestern and central Missouri and the Kansas City, Missouri area. The company was founded in 1923 and is headquartered in Springfield, Missouri. With 13.38 million shares outstanding and 1.36 million shares declared short as of May 2008, the failure to deliver in shares of GSBC has not been resolved and a buy-in is imminent. According to quarterly data provided by the SEC, there were still 38,750 shares of GSBC that were failing-to-deliver as of August 10, 2007.
Velocity Express Corp. (NASDAQ: VEXP | Quote | Chart | News | PowerRating) together with its subsidiaries, provides logistics solutions to consumers and businesses in the United States and Canada. It offers distribution logistics services, which include the receipt of customer bulk shipments that are divided and sorted at metropolitan locations and delivered to multiple locations; scheduled logistics services comprising daily pickup and delivery of parcels; and expedited logistics services, including expedited point-to-point service for customers with time sensitive delivery requirements. The company primarily serves customers operating in the healthcare, commercial and office products, financial, transportation and logistics, technology, and energy sectors. Velocity Express Corporation was founded in 1979 and is headquartered in Westport, Connecticut. With 2.83 million shares outstanding and 32,100 shares declared short as of May 2008, the failure to deliver in shares of VEXP has not been resolved and a buy-in is imminent. According to quarterly data provided by the SEC, there were still 12,601 shares of VEXP that were failing-to-deliver as of September 10, 2007.
LipidViro Tech, Inc. (OTCBB: LPVT | Quote | Chart | News | PowerRating) a biotechnology company, engages in the research and development of d-OSAB Therapy, a treatment targeting cardiovascular disease and stroke; and PathPure, a purification process for production of pathogen-free biologics. LipidViro d-OSAB Therapy is re-engineered doseable form of a traditional therapy, known as OSAB-uc for uncontrolled dosing. The company intends to commence a Phase IIa study for patients suffering from Ischemic Brain Stroke with LipidViro d-OSAB Therapy. It is conducting preclinical laboratory research focused on the development of therapeutics and biological products that utilize its proprietary d-OSAB platform, processes, and equipment. LipidViro Tech was founded in 2003 and is based in Salt Lake City, Utah. As of January 28, 2008, LipidViro Tech Inc. operates as a subsidiary of Jenson Services, Inc. With 18.06 million shares outstanding and an undisclosed short position, the failure to deliver in shares of LPVT has not been resolved and a buy-in is possible.
Imagexpres Corp. (OTC: IMJX | Quote | Chart | News | PowerRating) is a digital imaging and printing company, headquartered in Rochester, NY. ImageXpres develops imaging systems solutions for commercial printing, consumer photo, health and business communications market segments. ImageXpres is currently manufacturing and marketing a family of self-service multimedia kiosks, iPrint Digital Photo Kiosks, and LitePix Digital Displays, digital signs that provide unique advertising benefits for business owners. With 11.94 million shares outstanding and 253,300 shares declared short as of May 2008, the failure to deliver in shares of IMJX has not been resolved and a buy-in is imminent. According to quarterly data provided by the SEC, there were still 1,900,000 shares of IMJX that were failing-to-deliver as of September 20, 2007.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,050,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
